momentous events have occurred since my last letter to you. First,
we signed a memorandum of understanding between the UC Davis Cancer
Center and the Lawrence Livermore National Laboratory to develop
an integrated cancer program. This is a fully integrated partnership,
as exemplified by recent appointments of Lawrence Livermore National
Laboratory scientists to our cancer program. Dennis Matthews is
now the associate director for biomedical technology while Jim Felton
is associate director for cancer control and Ken Turteltaub is co-leader
of the molecular oncology program for the UC Davis Cancer Center.
can read more about projects that are either in progress or pending
in this issue. I am confident that we will see extraordinary and
exciting results from this union. The extraordinary speed by which
the collaboration took place attests to the sincerity of all involved,
and our belief that this collaboration will make a difference in
the fight against cancer.
the UC Davis Cancer Center's Phase II consortium grant, which includes
the City of Hope Medical Center and the University of Southern California,
was awarded $6.5 million by the National Cancer Institute. This
was the largest award given by the National Cancer Institute's Cancer
Therapy Evaluation Program (CTEP) this year. David Gandara, our
associate director for clinical research, submitted the contract
with able assistance from Primo Lara and Paul Gumerlock. We are
extremely proud of this achievement. It further demonstrates our
dedication to bringing the best and newest treatments to our patients.
the same time, we are working to understand the biology of cancer
so that patients in the future will have better and more successful
with the help of many and the extraordinary work of a dedicated
few, we have submitted our 627-page grant for cancer center designation
to NCI. The grant is built around six programs (molecular oncology,
cancer biology in animals, therapeutics, cancer control, prostate
cancer, and biomedical technology). It also includes six shared
resources (molecular pathology, optical biology, mouse biology,
pharmacokinetics, biostatistics, and clinical trials).
cancer center grant reveals a program that is truly integrated.
Sixty percent of the grant's members come from the School of Medicine,
20 percent from UC Davis programs such as the School of Veterinary
Medicine, the College of Agriculture and Science, the Department
of Nutrition and the Division of Biological Sciences, and 20 percent
are scientists at Lawrence Livermore National Laboratory.
patients throughout the region will only benefit from having this
infrastructure in place. I look forward to telling you more about
our progress in future issues of Synthesis.
W. deVere White, MD
Director, UC Davis Cancer Center
Table of Contents |
To our Readers |
Building on Basics
Focusing on Patients |
In Translation |
Campus Connection |
News in Brief
UC Davis Health System |
© 2000, 2001, 2002 UC Regents. All rights reserved.
UC Davis Cancer Center